Atezolizumab
- PDF / 169,710 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 102 Downloads / 182 Views
1 S
Tumour lysis syndrome: case report A 55-year-old woman developed tumour lysis syndrome (TLS) during treatment with atezolizumab for metastatic triple-negative breast cancer (mTNBC). The woman, who had a history of invasive ductal carcinoma of the left breast stage IIIA (T3N2) and mTNBC with extensive liver and bone metastasis, presented to the emergency department in January 2020. She had generalised body weakness, sleepiness, anorexia and oliguria for the past few days. Laboratory investigations revealed pancytopenia along with serum levels of uric acid 17.8 mg/dL, creatinine 4.5 mg/dL, potassium 5.5 mEq/L, phosphorus 5 mg/dL and calcium 9.3 mg/dL. Six days prior to the presentation, she received the first cycle of atezolizumab 840 mg/m2 [route and frequency not stated] and albumin-bound paclitaxel [nab-paclitaxel] for mTNBC. Subsequently, she was diagnosed with TLS secondary to the atezolizumab use. The woman was treated with aggressive unspecified IV hydration and rasburicase. Thereafter, a significant clinical improvement was noted along with complete resolution of TLS symptoms. Laboratory test revealed uric acid
Data Loading...
